| ||
Japanese firm buys Montana pharmaceutical company Businessweek BOZEMAN, Mont. (AP) — A Japanese pharmaceutical company is acquiring Bozeman-based LigoCyte Pharmaceuticals in a $60 million deal to expand its vaccine division, Takeda Pharmaceutical Co. announced. LigoCyte's work on a vaccine to prevent ... See all stories on this topic » | ||
Sagent Pharmaceuticals launches caffeine citrate injection and oral solution pharmabiz.com Sagent Pharmaceuticals, Inc. has launched caffeine citrate injection, USP and caffeine citrate oral solution, USP, central nervous system stimulants, in two latex-free vial presentations. According to IMS, for the 12 months ending July 2012, the US ... See all stories on this topic » | ||
90% of Pharmaceutical Professionals See Positive Business Environment in ... Sacramento Bee According to the survey, 97% of visitors expect sales to increase or stay the same over the next 12 months (up from 90% over the last 12 months), and 90% rate their business opportunity in the global pharmaceutical market positively. Attendees expect ... See all stories on this topic » | ||
Defective generic pill revives quality concerns CTV News The Food and Drug Administration on Wednesday asked Teva Pharmaceuticals to withdraw its drug Budeprion XL 300 after testing showed the drug did not properly release its key ingredient. The drug is supposed to be equivalent to GlaxoSmithKline's ... See all stories on this topic » | ||
Pfizer to challenge Indian ruling overturning cancer drug patent Economic Times Earlier this year, an Indian ruling allowed a local firm to produce a vastly cheaper copy of German pharmaceutical giant Bayer's patented drug Nexavar for liver and kidney cancer. India's patents chief ruled the price Bayer charged was "exorbitant" and ... See all stories on this topic » | ||
| ||
Canaccord Genuity Reaffirms Buy Rating on Watson Pharmaceuticals ... Jags Report Watson Pharmaceuticals Incorporated logo Canaccord Genuity reissued their buy rating on shares of Watson Pharmaceuticals Incorporated (NYSE: WPI) in a research report released on Friday morning. Canaccord Genuity currently has a $100.00 price target ... See all stories on this topic » | ||
Thallion Announces 2012 Third Quarter Results Stockhouse MONTRÉAL, QUÉBEC--(Marketwire - Oct. 5, 2012) - Thallion Pharmaceuticals Inc. (TSX:TLN) today announced its operational and financial results for the three-month and nine-month periods ended August 31, 2012. "The proceeds from the sale of Caprion ... See all stories on this topic » | ||
|
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Delete this alert.
Create another alert.
Manage your alerts.
0 comments:
Post a Comment